KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Operating Expenses (2019 - 2025)

GoodRx Holdings' Operating Expenses history spans 7 years, with the latest figure at $172.1 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 4.6% year-over-year to $172.1 million; the TTM value through Dec 2025 reached $709.4 million, down 2.36%, while the annual FY2025 figure was $709.4 million, 2.36% down from the prior year.
  • Operating Expenses for Q4 2025 was $172.1 million at GoodRx Holdings, down from $181.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $218.3 million in Q3 2023 and bottomed at $165.4 million in Q1 2021.
  • The 5-year median for Operating Expenses is $181.1 million (2024), against an average of $185.5 million.
  • The largest YoY upside for Operating Expenses was 117.0% in 2021 against a maximum downside of 55.52% in 2021.
  • A 5-year view of Operating Expenses shows it stood at $201.5 million in 2021, then dropped by 9.49% to $182.4 million in 2022, then increased by 17.85% to $214.9 million in 2023, then fell by 16.07% to $180.4 million in 2024, then decreased by 4.6% to $172.1 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Operating Expenses are $172.1 million (Q4 2025), $181.4 million (Q3 2025), and $176.3 million (Q2 2025).